Celltrion announced on June 18 that it conducted an animal efficacy test for Rekirona (CT-P59, regdanvimab), its COVID-19 antibody treatment. As a result, the test showed efficacy in treating the South African beta variants.
In the test, Celltrion injected Rekirona into 50 laboratory mice infected with COVID-19. The company confirmed clinical improvements including the significant decrease in virus titer and reduced weight loss in the group treated with Regkirona compared to the control group that did not receive any treatment.
Celltrion also confirmed that even at doses lower than the clinically applied dose in the previous test on Ferrets, confirming the high neutrality of Rekirona. In addition, the survival rate of Rekirona group was 100 percent, while that of the control group was only 50 percent.
In April, Celltrion conducted an animal efficacy on ferrets against South African variants (Beta) for Regkirona. In this experiment, the results showed no significant difference in virus neutrality compared to the wild-type virus.
The results are published in Biochemical and Biophysical Research Communications (BBRC) journal.
Celltrion is also conducting animal efficacy tests on India variants (Delta) and Brazilian variants (Gamma) following the South African variants (Beta). The results will be announced as early as next month.
